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Background: To date, only two prospective trials have compared drug-eluting stents (DES) with bare metal stents (BMS) in saphenous vein graft 
(SVG) lesions, with conflicting results.  The frequency and factors associated with DES use in SVG lesions in contemporary practice is unknown.
Methods: We analyzed the frequency and factors associated with DES use in patients undergoing SVG stenting from January 1, 2004 to March 
31, 2009 in the National Cardiovascular Data Registry (NCDR). Generalized estimating equations logistic regression modeling was used to generate 
independent variables associated with DES use in SVGs.
Results: During the study period, percutaneous coronary intervention (PCI) of a SVG represented 5.7% of the total PCI volume (91,355 of 
1,596,966). Of the 84,875 patients who received a SVG stent, a DES was used in 64.5%. Unfractionated heparin was used in 46%, enoxaparin in 
17%, bivalirudin in 42%, and a glycoprotein IIb/IIIa inhibitor in 40%. On multivariable analysis, several parameters were associated with DES use 
(Table).
Conclusions: In spite of limited safety and efficacy data, DES are currently used in nearly two thirds of SVG lesions. Several clinical parameters 
(such as the time period of implantation and the complexity of coronary artery disease) are associated with the decision to implant a DES in these 
challenging lesions.
Variables associated with DES use in SVG lesions
Variable Odd ratio Lower 95% CI Upper 95% CI Chi-square p
Year-quarter 0.91 0.91 0.92 706 <0.0001
Multivessel PCI 2.03 1.92 2.15 642 <0.0001
Prior PCI 1.40 1.36 1.44 479 <0.0001
Acute myocardial infarction 0.78 0.75 0.81 168 <0.0001
Smoking 0.78 0.75 0.81 152 <0.0001
SVG body lesion (vs. distal) 0.67 0.64 0.70 80 <0.0001
SVG aortic anastomotic lesion (vs. distal) 0.76 0.72 0.81 <0.0001
Warfarin use 0.76 0.71 0.81 74 <0.0001
Age (per 5 year increase) 0.96 0.95 0.97 69 <0.0001
